AI Article Synopsis
- Researchers measured nitrosylhemoglobin (HbNO) levels as an indicator of blood nitric oxide (NO) using a specific method in rats treated with L-NAME, which caused significant hypertension and reduced HbNO levels.
- Oral administration of olmesartan, an angiotensin II receptor blocker, not only improved blood pressure in these rats but also increased HbNO levels, indicating it may positively influence nitric oxide dynamics.
- In contrast, hydralazine also improved hypertension but did not affect HbNO levels, suggesting that olmesartan may be more effective in addressing endothelial dysfunction related to decreased NO.
Article Abstract
We previously succeeded in measuring the nitrosylhemoglobin (HbNO) level as an index of blood nitric oxide (NO) by the electron paramagnetic resonance (EPR) HbNO signal subtraction method. In this study, we examined the effects of olmesartan, an angiotensin II type 1 receptor blocker (ARB), on NO dynamics in N(omega)-nitro-L-arginine methyl ester (L-NAME)-treated rats by the EPR-subtraction method. Oral administration of L-NAME for 2 weeks induced serious hypertension, and the HbNO concentration was reduced to 37.6% of the level in controls. Coadministration of olmesartan improved hypertension and increased the blood HbNO concentration of L-NAME-treated rats. In contrast, coadministration of hydralazine improved hypertension but did not affect the blood HbNO concentration. In conclusion, our findings suggested that chronic administration of olmesartan ameliorated the endothelial dysfunction in L-NAME-treated rats.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1291/hypres.29.369 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!